Maymetsi

Active Ingredient:: Metformin Hydrochloride, Sitagliptin
Origin:: EU

Maymetsi (Metformin Hydrochloride, Sitagliptin)

Q: What is Maymetsi used for?

Maymetsi is prescribed for the treatment of type 2 diabetes mellitus in adults. It is indicated when diet and exercise alone do not achieve adequate glycemic control, and it can be used as monotherapy or in combination with other antidiabetic agents such as insulin or sulfonylureas.

Q: How does Metformin Hydrochloride and Sitagliptin work?

Metformin Hydrochloride lowers blood glucose by decreasing hepatic glucose production and improving peripheral insulin sensitivity. Sitagliptin blocks the DPP‑4 enzyme, which prolongs the activity of incretin hormones (GLP‑1 and GIP), leading to increased insulin secretion and reduced glucagon release in a glucose‑dependent manner. Together they provide complementary glucose‑lowering effects.

Q: What is the usual dose of Maymetsi?

The dose of Maymetsi is individualized and set by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. The prescriber determines the appropriate strength, frequency, and any necessary titration schedule.

Q: Is Maymetsi safe in pregnancy or breastfeeding?

Safety data for Maymetsi in pregnancy and lactation are limited. It should only be used during pregnancy or while breastfeeding if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

Q: How do I order Maymetsi from GNH India?

To order Maymetsi, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and import documentation.

Q: How does Maymetsi compare with other antidiabetic options?

Maymetsi combines two mechanisms—biguanide action of metformin and DPP‑4 inhibition of sitagliptin—offering greater HbA1c reduction than either agent alone. Compared with monotherapy, the combination can achieve better glycemic control without a proportional increase in hypoglycemia risk, making it a convenient option for patients needing dual therapy.

Q: How should Maymetsi be stored and handled?

Maymetsi tablets should be stored below 25 °C in their original container, protected from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Q: How is Maymetsi administered?

Maymetsi is taken orally, usually with a glass of water. It can be taken with or without meals, but consistent timing with respect to meals helps maintain stable blood levels. Patients should follow the dosing schedule prescribed by their healthcare provider.

Q: What are the most serious risks to watch for while taking Maymetsi?

The most serious risks include lactic acidosis, which presents with muscle pain, rapid breathing, or abdominal discomfort, and pancreatitis, indicated by severe abdominal pain and elevated enzymes. Additionally, severe allergic reactions such as rash, angioedema, or anaphylaxis require immediate medical attention.

Q: Who should not use Maymetsi?

Maymetsi should be avoided in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin, sitagliptin, or any component of the formulation, and in those with a history of lactic acidosis. Caution is also advised for patients with significant liver disease.

Metformin Hydrochloride and Sitagliptin, the active ingredient in Maymetsi, is a biguanide and DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of type 2 diabetes mellitus in adult patients when diet and exercise alone are insufficient.

GNH India supplies Maymetsi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company emphasizes quality assurance and regulatory compliance in all shipments. Maymetsi is manufactured under EU Good Manufacturing Practice standards and is distributed to meet global demand.

Manufacturer / TM Owner

Krka, D.D., Novo Mesto

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Maymetsi, a combination of metformin and sitagliptin, is used in the management of type 2 diabetes mellitus.

Type 2 diabetes mellitus: improves overall glycemic control when diet and exercise are insufficient.
Adjunct to insulin therapy: enhances glucose regulation in patients requiring additional lowering of blood glucose.
Combination therapy: reduces HbA1c levels more effectively than either component alone.

How It Works

Metformin Hydrochloride reduces hepatic gluconeogenesis and increases peripheral insulin sensitivity, thereby lowering fasting glucose production. Sitagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, prolonging the activity of incretin hormones (GLP‑1 and GIP) which enhances glucose‑dependent insulin secretion and suppresses glucagon release. The complementary actions of both agents provide significantly additive glucose‑lowering effects without causing hypoglycemia when used alone in patients.

Side Effects

Maymetsi may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea.
Headache: mild to moderate intensity.
Hypoglycemia (when combined with insulin or sulfonylureas): symptoms of low blood sugar.

Serious or Rare Side Effects

Lactic acidosis: a rare but potentially fatal metabolic complication.
Pancreatitis: severe abdominal pain with elevated enzymes.
Severe allergic reactions: rash, angioedema, or anaphylaxis.
Hepatic dysfunction: abnormal liver enzymes or hepatitis.
Renal impairment worsening: especially in patients with pre‑existing kidney disease.

Precautions & Warnings

Before prescribing Maymetsi, several safety considerations should be evaluated.

Renal function assessment: avoid use in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²).
Hepatic impairment monitoring: use with caution in patients with liver disease.
Risk of lactic acidosis: discontinue if signs of metabolic acidosis appear.
Hypoglycemia vigilance: monitor blood glucose when used with insulin or sulfonylureas.
Pregnancy and lactation: only use if potential benefit justifies potential risk to fetus or infant.
Store below 25°C: keep in the original packaging, protect from moisture and light.

Avoid Interactions

Maymetsi can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

Iodinated contrast agents: may precipitate acute renal failure when combined with metformin.
Concomitant use with other DPP‑4 inhibitors: increases risk of adverse effects without added benefit.
Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise sitagliptin plasma levels.

Moderate Interactions (Monitor Closely)

Insulin or sulfonylureas: increased risk of hypoglycemia.
Diuretics (e.g., furosemide): may affect renal clearance of metformin.
Cimetidine: can raise metformin concentrations.

Frequently Asked Questions

Maymetsi is prescribed for the treatment of type 2 diabetes mellitus in adults. It is indicated when diet and exercise alone do not achieve adequate glycemic control, and it can be used as monotherapy or in combination with other antidiabetic agents such as insulin or sulfonylureas.

Metformin Hydrochloride lowers blood glucose by decreasing hepatic glucose production and improving peripheral insulin sensitivity. Sitagliptin blocks the DPP‑4 enzyme, which prolongs the activity of incretin hormones (GLP‑1 and GIP), leading to increased insulin secretion and reduced glucagon release in a glucose‑dependent manner. Together they provide complementary glucose‑lowering effects.

The dose of Maymetsi is individualized and set by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. The prescriber determines the appropriate strength, frequency, and any necessary titration schedule.

Safety data for Maymetsi in pregnancy and lactation are limited. It should only be used during pregnancy or while breastfeeding if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Maymetsi, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and import documentation.

Maymetsi combines two mechanisms—biguanide action of metformin and DPP‑4 inhibition of sitagliptin—offering greater HbA1c reduction than either agent alone. Compared with monotherapy, the combination can achieve better glycemic control without a proportional increase in hypoglycemia risk, making it a convenient option for patients needing dual therapy.

Maymetsi tablets should be stored below 25 °C in their original container, protected from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Maymetsi is taken orally, usually with a glass of water. It can be taken with or without meals, but consistent timing with respect to meals helps maintain stable blood levels. Patients should follow the dosing schedule prescribed by their healthcare provider.

The most serious risks include lactic acidosis, which presents with muscle pain, rapid breathing, or abdominal discomfort, and pancreatitis, indicated by severe abdominal pain and elevated enzymes. Additionally, severe allergic reactions such as rash, angioedema, or anaphylaxis require immediate medical attention.

Maymetsi should be avoided in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin, sitagliptin, or any component of the formulation, and in those with a history of lactic acidosis. Caution is also advised for patients with significant liver disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 01 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.